CN1686101A - New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food - Google Patents
New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food Download PDFInfo
- Publication number
- CN1686101A CN1686101A CNA2005100206490A CN200510020649A CN1686101A CN 1686101 A CN1686101 A CN 1686101A CN A2005100206490 A CNA2005100206490 A CN A2005100206490A CN 200510020649 A CN200510020649 A CN 200510020649A CN 1686101 A CN1686101 A CN 1686101A
- Authority
- CN
- China
- Prior art keywords
- linolenic
- medicine
- gout
- linolenic acid
- health food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
An application of linolenic acid in preparing the anti-gout medicine and health-care food from it in conjunction with acceptable carrier and VE is disclosed.
Description
(1) technical field:
The present invention relates to linolenic new purposes, particularly linolenic acid in the medicine of preparation gout or the new purposes in the health food; The invention still further relates to the linolenic acid medicine or the health food of the gout that is Main Ingredients and Appearance.
(2) background technology:
Gout is the disease that purine metabolic disturbance causes, it is too much to show as in the blood uric acid, cause urate deposition in the joint, kidney and connective tissue, cause joint deformity, nephropathy and concurrent renal calculus.The acute attack of gout is to cause the pain that granulocyte local infiltration and inflammatory reaction are followed owing to be deposited on the urate crystal in joint.The medicine of doctor trained in Western medicine gout can be divided into: suppress the uricopoiesis medicine, as allopurinol; Promote the urate excretion medicine, as probenecid, sulfinpyrazone, benzbromarone; Treatment acute gout medicine is as colchicine and some anti-inflammatory analgesic such as indomethacin, Phenylbutazone and naproxen etc.But the said medicine toxic and side effects is big, causes side effect such as allergy, bone marrow depression as allopurinol; Probenecid can cause gastrointestinal disturbance, renal colic and bring out the gout acute attack; The toxicity of colchicine is very big, can cause nausea,vomiting,diarrhea, occurs pharyngeal causalgia, bloody diarrhea, hematuria, shock during acute poisoning, can suppress hemopoietic function of bone marrow, and long-time medication can cause granulocyte and thrombocytopenia, aplastic anemia.Because above-mentioned drug side effect is very big, the patient often can not adhere to taking for a long time, makes gout be difficult to radical cure.The traditional Chinese medical science thinks that then gout belongs to categories such as arthromyodynia, gout, severe and migratory arthralgia, be exopathogen retardance meridians, coagulation of QI-blood, the pain of joint muscle numbness that Liver and kidney two void cause, weighing, the disease of joint stuffiness, chronic patient has that joint deformity is stiff more, tophus, nephropathy etc.Chinese medical discrimination can be divided into the hot and suffocating card of rheumatism, blockage of phlegm and blood stasis card, the positive deficiency syndrome of lingering arthralgia again, and clinical treatment often adopts sides such as clearing heat and expelling damp, disperse blood stasis and dredge collateral, supplementing QI and nourishing YIN.For example the Chinese medicine of clearing away heat-damp and promoting diuresis comprises Flos Lonicerae, Fructus Forsythiae, Radix Scutellariae, Cortex Phellodendri, Rhizoma Polygoni Cuspidati, Rhizoma Alismatis, Herba Artemisiae Annuae, Herba Hedyotidis Diffusae etc., and the Chinese medicine of blood circulation promoting and blood stasis dispelling comprises Herba sambuci chinensis, Caulis Spatholobi, Semen Persicae, Flos Carthami etc.Because the treatment by Chinese herbs gout is all based on compound recipe, the side effect of various degrees, its curative effect is not remarkable, takes inconvenient yet.Therefore, all difficult therapeutic effect that makes patient satisfaction that reaches of the anti-gout drugs of the existing doctor trained in Western medicine and the traditional Chinese medical science.
Linolenic acid claims alpha-linolenic acid again, and its structural formula is:
CH
3CH
2CH＝CHCH
2CH＝CHCH
2CH＝CH(CH
2)
7COOH
Linolenic acid is the fatty acid of needed by human, be that N-3 is the parent that fatty acid is closed in insatiable hunger in the formation human body, but metabolism produces multiple important active substances such as DHA, EPA in human body.Modern science research thinks that linolenic acid is to maintain the core substance that human brain is evolved, and its final metabolite EPA and DHA are the important component of forming neuron membrane.Modern medicine and threpsology also confirm: alpha-linolenic acid not only has effects such as the central nervous system of adjusting, improving memory, nootropics and visual function, also have the sleep of improvement, control cardiovascular and cerebrovascular disease, improve blood vessel elasticity, two-ways regulation blood pressure, blood fat, cholesterol, prevention myocardial infarction and cerebral embolism, reach the promotion insulin secretion, prolong hypoglycemic effect, suppress physiological functions such as complication.In a single day human body lacks alpha-linolenic acid promptly can cause the body metabolism disorder of blood lipid, causes hyperlipidemia, high blood viscosity, atherosclerosis; Also can cause immunity reduction, forgetful, tired, visual deterioration; If especially infant, teenager lack the normal development that will have a strong impact on its intelligence and vision.Therefore, alpha-linolenic acid is preparation prevention and treatment hyperlipidemia, high blood viscosity, coronary heart disease, diabetes, fatty liver, senile dementia and improves the medicine of brain effect or the important source material of health food.For example application number is: 00109537.4, name is called: the Chinese invention patent of " a kind of medicine of preventing and treating cardiovascular and cerebrovascular disease ", disclose a kind of medicine of preventing and treating cardiovascular and cerebrovascular disease, it is to be the capsule made of raw material and the compositions of soft capsule with the total Saponin powder of Herba Gynostemmatis, nucleic acid powder, soybean lecithin powder, tea polyphenols, Eriocheir sinensis powder, linolenic acid, fish oil, Oleum sesami; This medicine has better curative effect to cardiovascular and cerebrovascular disease such as treatment hyperlipidemia, atherosclerosis, hypertension, coronary heart disease, myocardial infarction, cerebral infarction.But not finding as yet so far linolenic acid is applied to gout or occurs with the linolenic acid is the anti-gout drugs or the health food of feedstock production.
(3) summary of the invention:
The present invention will disclose linolenic new purposes, promptly in the medicine of preparation gout or the new purposes in the health food.The applicant finds with the linolenic acid to be that the medicine or the health food of feedstock production can play the gout effect, for constitutional and secondary hyperuricemia, and the hyperuricemia that too much causes of uricopoiesis especially; Take place repeatedly or chronic gout; Tophus; Uric acid renal calculus and/or urate nephropathy; The hyperuricemia that renal insufficiency is arranged; The acute attack of the acute attack of gouty arthritis and prevention of recurrence gouty arthritis all can be played excellent prevention or therapeutic effect.
The present invention is directed to the doctor trained in Western medicine and the traditional Chinese medical science deficiency aspect gout, disclosing a kind of is the medicine or the health food of the gout of feedstock production with the linolenic acid, and this medicine or health food comprise acceptable carrier on the linolenic acid of effective dose and various medicine and the food; Certainly can also in prescription, add a certain amount of antioxidant vitamin E; The proportional quantity of linolenic acid and vitamin E can be the linolenic acid of effective dose be equipped with medically can use amount vitamin E, but the proportioning between them is preferably by weight percentage: linolenic acid 90～99.5%; Vitamin E 0.5～10%; Wherein said linolenic acid can certainly be selected other the higher material of linolenic acid content for containing linolenic oils and fats or free fatty or ethyl linolenate; And containing in the linolenic material of selecting for use, linolenic content should be 10～99%, and its preferred content is 60～80%; Preferably then be 70%.
According to above-mentioned prescription, can be directly with each component fill soft capsule; Or be processed into microscapsule powder, further be processed into tablet or fill hard capsule, or make other medicine or food on acceptable forms.Made contain linolenic anti-gout drugs or health food should be oral, one after each meal, adult's usual amounts contains 1～2 linolenic medicine of gram or health food, 2 times on the one for take at every turn.
The applicant has found and linolenic acid can be applied to gout, and to have developed be the medicine or the health food of the gout of feedstock production with the linolenic acid, this production technology is simple, with low cost, the gout effect is remarkable, and short treating period is difficult for recurrence, and without any side effects, take also very convenient.
(4) specific embodiment:
Embodiment one:
Get ethyl linolenate (linolenic acid content 70%) 99.5 grams, vitamin E 0.5 gram uniform mixing, the fill soft capsule promptly obtains the gout capsule.
Embodiment two:
It is fully emulsified to get Oleum Perillae (linolenic acid content 55%) 50 gram, carboxylated dextrin 150 grams, water 300 grams, spends spray dryinges in inlet temperature 90 degree and outlet temperature 40, makes Powdered Oleum Perillae microcapsule.This product can be used for producing health foods such as cookies, bread, dessert, ice cream, soup stock, sauce, milk product; Also direct fill hard capsule obtains the gout capsule.
Embodiment three:
Get Semen Lini oil (linolenic acid content 40%) 90 gram, vitamin E 10 grams, prepare Powdered microcapsule, can be used for producing various health foods according to the method for embodiment two; Or direct fill hard capsule, obtain the gout capsule.
Test example one:
Mr. Zheng, the man in year surplus in the of 50, suffers from gout for many years, toe joint, finger and elbow joint pain, it is weak to feel tired, adhere to taking every day contain 1 the gram linolenic embodiment one described gout capsule, took in 1st 2 times, take one week of this capsule back gout transference cure, feel energetic, exceed half a year so far and do not recur.
Test example two:
Mr. Wang, the man, 40 years old, suffer from gout for many years, toe joint has an intense pain down to difficulty in walking, adheres to taking every day containing the linolenic embodiment one described gout capsule of 2 grams, took 2 times in 1st, transference cure after the week, three wheat harvesting periods do not recur so far.
Test example three:
Mr. Huang, the man, in year surplus in the of 40, the trouble gout is pointed and elbow joint pain for many years, adheres to taking every day containing the linolenic embodiment one described gout capsule of 1.5 grams, took 2 times in 1st, two all backs transference cures, four wheat harvesting periods do not recur so far.
Claims (8)
1, linolenic acid is in the medicine of preparation gout or the new purposes in the health food.
2, a kind of medicine of gout or health food is characterized in that: comprise effective dose linolenic acid and medicine and food on acceptable carrier.
3, the medicine of gout according to claim 2 or health food is characterized in that: also comprise vitamin E.
4, the medicine of gout according to claim 3 or health food is characterized in that the proportioning of described linolenic acid and vitamin is by weight percentage: linolenic acid 90～99.5%; Vitamin E 0.5～10%.
5, according to the medicine or the health food of any one described gout in the claim 2～4, it is characterized in that: described linolenic acid is for containing linolenic oils and fats or containing linolenic free fatty or contain linolenic ethyl ester.
6, the medicine of gout according to claim 5 or health food is characterized in that: contain linolenic oils and fats or contain linolenic free fatty or contain that linolenic content is 10～99% in the linolenic ethyl ester.
7, the medicine of gout according to claim 6 or health food is characterized in that: contain linolenic oils and fats or contain linolenic free fatty or contain that linolenic content is 60～80% in the linolenic ethyl ester.
8, the medicine of gout according to claim 7 or health food is characterized in that: contain linolenic oils and fats or contain linolenic free fatty or contain that linolenic content is 70% in the linolenic ethyl ester.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100206490A CN100381121C (en) | 2005-03-30 | 2005-03-30 | New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100206490A CN100381121C (en) | 2005-03-30 | 2005-03-30 | New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686101A true CN1686101A (en) | 2005-10-26 |
| CN100381121C CN100381121C (en) | 2008-04-16 |
Family
ID=35304142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100206490A Expired - Fee Related CN100381121C (en) | 2005-03-30 | 2005-03-30 | New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100381121C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113812614A (en) * | 2021-03-04 | 2021-12-21 | 孙晓辉 | Uric acid resistant functional food |
-
2005
- 2005-03-30 CN CNB2005100206490A patent/CN100381121C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113812614A (en) * | 2021-03-04 | 2021-12-21 | 孙晓辉 | Uric acid resistant functional food |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100381121C (en) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105727081A (en) | Healthcare product composition for treating gout | |
| CN105412623A (en) | Medicament for treating fatty liver, prostatitis, nephralgia, nephritis, hypertension and diabetes | |
| CN104825816A (en) | Medicine for treating fatty liver, prostatitis, diabetes, nephralgia and kidney deficiency | |
| CN102551046A (en) | Natural health composition for weight reduction and application of same | |
| CN102423413A (en) | Medicament for treating hyperlipemia and fatty liver and preventing atherosclerosis as well as applications thereof | |
| CN1099835C (en) | Antilipemic beverage or tea | |
| CN102641469B (en) | Medicinal composition for preventing or treating nonalcoholic steatohepatitis | |
| CN100381121C (en) | New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food | |
| CN103735623A (en) | Auxiliary blood fat reducing tablet | |
| CN101427720A (en) | High-concentration infusion tea for treating diabetes and method of producing the same | |
| CN101259191B (en) | Fat-reducing health products and producing method thereof | |
| CN103735603B (en) | A kind of compound antihyperglycemic soft capsule and preparation method thereof | |
| CN101263910A (en) | Fat-reducing science and technology cooking | |
| CN1788581A (en) | Preparation method of fat-reducing blood sugar-reducing milk powder containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder | |
| CN100467043C (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN107232380A (en) | It is a kind of to help to improve lycium ruthenicum candy of sclerotin and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN106491922B (en) | Traditional Chinese medicine formula medicine suitable for qi stagnation and turbid phlegm type hyperlipemia and capsule thereof | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN1850160A (en) | Qidantongmai Tablet, and its preparing process | |
| CN1739776A (en) | Chinese herbal medicine decoction for treating senile dementia caused by marrow sea deficiency | |
| CN1935247A (en) | Medicinal composition for treating adiposis or hyperlipemia | |
| CN105661506A (en) | Health-care food composition having function of reducing weight and production method of health-care food composition | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN102755444A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080416 |